PMID: 9657Jul 9, 1976

Changes in brain norepinephrine associated with sensitization to d-amphetamine

P H Short, L Shuster


Pretreatment of B6AF1/J mice with d-amphetamine HCl 10 mg/kg, twice daily for 5 days, produced a 4-fold increase in the running response to a test dose of 5 mg/kg amphetamine. Amphetamine pretreatment decreased whole-brain norepinephrine levels to 50% of control values and whole-brain dopamine to 85%. The test dose of 5 mg/kg amphetamine lowered whole brain norepinephrine levels of control mice from 0.50 mug/g to 0.28 mug/g in 2 h. In amphetamine-pretreated mice, this injection caused an increase in whole-brain norepinephrine levels from 0.22 mug/g to 0.55 mug/g at 30 min, followed by a decrease to 0.22 mug/g at 60 min. No change in whole brain dopamine levels was observed in either group. Amphetamine sensitization and norepinephrine depletion were still evident 25 days after pretreatment. No cross sensitization to morphine or cocaine was observed. Reserpine pretreatment resulted in a 3-fold increase in locomotor activity following injection of d-amphetamine, 5 mg/kg. No sensitization or changes in catecholamine levels were observed in amphetamine-treated A/J mice. These results suggest that the sensitization produced by amphetamine pretreatment may be related to the depletion of brain norepinephrine.


Jun 19, 1975·Psychopharmacologia·L ShusterB E Eleftheriou
Dec 1, 1974·European Journal of Pharmacology·C Ranje, U Ungerstedt
Oct 8, 1971·Nature·B A Campbell, H C Fibiger
May 1, 1969·European Journal of Pharmacology·L Magos
Oct 1, 1952·Journal of the American Pharmaceutical Association·J W E HARRISSONJ L AMBRUS
Mar 1, 1953·British Journal of Pharmacology and Chemotherapy·P B DEWS
May 15, 1962·Experientia·J van ROSSUMJ A HURKMANS
Aug 1, 1963·British Journal of Pharmacology and Chemotherapy·M D DAY, M J RAND


Mar 14, 1979·Psychopharmacology·H Y MeltzerV S Fang
Jan 1, 1982·Psychopharmacology·L ShusterD Righi
Apr 29, 1977·Psychopharmacology·L ShusterA Bates
Apr 15, 1979·European Journal of Pharmacology·P Muller, P Seeman
May 1, 1977·Pharmacology, Biochemistry, and Behavior·R G Browne, D S Segal
Dec 1, 1981·Pharmacology, Biochemistry, and Behavior·M Hirabayashi, M R Alam
Sep 1, 1981·Pharmacology, Biochemistry, and Behavior·N J Leith, R Kuczenski
Jul 1, 1992·Pharmacology, Biochemistry, and Behavior·T YamamuraH Ouchi
Mar 1, 1996·Pharmacology, Biochemistry, and Behavior·G I ElmerR B Rothman
Sep 1, 1993·Brain Research. Brain Research Reviews·T E Robinson, K C Berridge
Jul 1, 1997·Pharmacology, Biochemistry, and Behavior·T J PhillipsC N Lessov
Jul 27, 1999·Pharmacology, Biochemistry, and Behavior·K K SzumlinskiS D Glick
Nov 21, 2001·Drug and Alcohol Dependence·H L KimmelM J Kuhar
Sep 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D M CampT E Robinson
Jul 1, 1978·The Journal of Pharmacy and Pharmacology·C McManusP Seeman
May 1, 1993·The Journal of Pharmacy and Pharmacology·M Hirabayashi, S Tadokoro
Sep 25, 2010·The Journal of Pharmacology and Experimental Therapeutics·Barbara J CaldaroneAfshin Ghavami
Dec 17, 2008·Journal of Psychopharmacology·J A MilsteinT W Robbins

Related Concepts

Brain Chemistry
Mice, Inbred Strains
Norepinephrine, (+, -)-Isomer
Tyrosine 3-Monooxygenase

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.